The article by Tsai et al. in Annals 1 describes a significant inverse association between total serum bilirubin and total white (blood) cell count (WCC) in a cohort of healthy Taiwanese adults. This relationship was detected in cross-sectional data for cases with total serum bilirubin within the reference interval and total WCC less than 15 Â 10 9 /L. We have investigated similar relationships in two distinct cohorts of Australian patients who had routine pathology conducted via Sullivan Nicolaides Pathology (Taringa, Queensland), including assessments of inflammatory markers.
The first cohort consisted of community patients (n ¼ 980), and included cases tested for hepatitis B surface antigen (HBsAg) (n ¼ 510). The second cohort consisted of intensive care unit (ICU) cases from Brisbane Hospital (n ¼ 955). Ages ranged between 17 and 94 years for both cohorts, but with a higher mean age for the ICU cohort (66 years versus 40 years). Fiftyseven per cent (57%) of the ICU cohort was male, while 42% of the community cohort was male. Bivariate correlation (Pearson) was conducted to assess the association in each cohort between total serum bilirubin and total WCC (SPSS, version 22).
In order to reflect the Tsai et al. study, cases with elevated serum bilirubin (>20 mmol/L) and WCC (>12 Â 10 9 /L) were removed from the community cohort prior to analysis. A significant inverse correlation was detected between bilirubin and WCC (r ¼ À0.195, P < 0.001, n ¼ 833). Significant inverse correlations were also found separately for HBsAg positive cases (n ¼ 340, r ¼ À0.223, P < 0.001), and cases not tested for HBsAg (n ¼ 402, r ¼ À0.155, P < 0.005), but not the HBsAg negative cases (n ¼ 91, r ¼ À0.190, P > 0.07). The same analyses were performed on the total cohort (including cases with elevated bilirubin and/or WCC); no significant correlations were observed.
By contrast, in the ICU cohort, with all cases included, a significant positive correlation was found between total serum bilirubin and WCC (n ¼ 955, r ¼ 0.152, P < 0.001), whereas after the removal of elevated bilirubin and WCC cases, a significant association was not found (n ¼ 498, r ¼ 0.062, P > 0.16).
Our findings in the community cohort agree with the findings of the Tsai study. The association was also observed in a subcohort of HBsAg positive cases where increased acute inflammation might reasonably have been expected. We speculate that the inverse association between bilirubin and WCC seen in apparently healthy subjects reflects homeostasis in terms of normal variations of oxidative stress required to maintain health.
The opposite was found for high-dependency patients requiring intensive care. In this cohort, acute inflammation and multi-system disease processes resulted in a significant positive correlation between bilirubin and WCC. Consistent with this explanation, elevated inflammatory markers were seen in the ICU cohort, with ICU median CRP, ESR and WCC significantly higher compared with the community cohort (30 mg/mL versus 2 mg/mL; 18.5 mm h versus 6 mm h; and 11.1 Â 10 9 /L versus 6.8 Â 10 9 /L, respectively: all P < 0.001, Mann-Whitney U test). 
Reference change values using more than two results
We read with interest the article by Lund et al. on the calculation of limits for reference change values (RCV) in serial results. 1 They describe that as the number of results increases there is an increase in the RCV. This is due to the increased chance of false positives that may be encountered when using multiple results and is a consequence of the underlying concept which compares each individual successive result with the initial result.
An alternate concept may be to consider subsequent results as repeat testing which collectively provide an estimate of the new homeostatic set point. In contrast to Lund et al., as the number of results increases, with this view, the RCV decreases. The RCV also decreases if multiple results are available to estimate the initial set point.
Given n samples, the uncertainty of the estimate of an individual's homeostatic set point is reduced by multiplying the combined analytical and within-subject biological variation (CV AþI ) by a factor of 1/n ½ . 2 Consequently for n 1 results around an initial set point and n 2 results around a new set point, RCV ¼ Z Â CV AþI Â (1/n 1 þ 1/n 2 ) ½ , where Z is the Z-score corresponding to the desired level of significance of bidirectional or unidirectional change (commonly 1.96 for 95% probability of a true change in either direction). As n 1 and/or n 2 increase, the change required for a significant difference decreases (see Table 1 ). For example, with n 1 ¼ 4 and n 2 ¼ 2, RCV decreases by 39% compared to the traditional RCV calculation using two singleton measurements (n 1 ¼ n 2 ¼ 1). This reduction is irrespective of the Z-score selected. By way of example, using the case modelled by Lund et al., 1 from a starting haemoglobin concentration of 6.0 mmol/L (97 g/L) and CV AþI of 3.02% with four following samples, a rise to an average of 6.4 mmol/L (103 g/L) is significant in the proposed model, by comparison with their calculation where a single result of 6.6 mmol/L (106 g/L) is required to reach 95% confidence of a true change, indicating a reduction in the RCV of approximately 30%.
Assumptions included in this model include that the measurements follow a Gaussian distribution around respective homeostatic set points before and after a possible clinical event and that that any change in set point has completely occurred between measurements, such that results included in the calculation reflect steady state before and after the change. In practice, Table 1 . RCV using multiple estimates of the initial and new set points, expressed as a fraction of traditional RCV from two singleton measurements. 
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